{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:04:19Z","timestamp":1777388659112,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Research Foundation of Beijing Friendship Hospital","award":["No. yyqdkt2019-30"],"award-info":[{"award-number":["No. yyqdkt2019-30"]}]},{"name":"Cultivation Scientific Research Foundation of Capital Medical University","award":["No. 1210020247"],"award-info":[{"award-number":["No. 1210020247"]}]},{"DOI":"10.13039\/501100010270","name":"Capital Health Research and Development of Special Fund","doi-asserted-by":"publisher","award":["No.2018-2-2182"],"award-info":[{"award-number":["No.2018-2-2182"]}],"id":[{"id":"10.13039\/501100010270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science & Technology Commission","doi-asserted-by":"crossref","award":["No. Z181100001718070"],"award-info":[{"award-number":["No. Z181100001718070"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Beijing Municipal Health Commission, Special Program of Scientific Research on health development in Beijing","award":["grants shoufa 2018-2-2023"],"award-info":[{"award-number":["grants shoufa 2018-2-2023"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["grants 61871276\uff0c82071876"],"award-info":[{"award-number":["grants 61871276\uff0c82071876"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support","award":["No. ZYLX202101"],"award-info":[{"award-number":["No. ZYLX202101"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>We aimed to evaluate the value of using preoperative magnetic resonance imaging (MRI) features and clinical indicators to predict the early response of hepatocellular carcinoma (HCC) to transcatheter arterial chemoembolization (TACE). We also aimed to establish a preoperative prediction model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively reviewed data of 111 patients with HCC who underwent magnetic resonance imaging (MRI) before the first TACE and underwent MRI or computed tomography between 30 and 60\u00a0days after TACE. We used the modified response evaluation criteria in solid tumors for evaluating the TACE response. We used univariate and multivariate logistic regression analyses to identify independent predictors based on MRI features and clinical indicators. Moreover, receiver operating characteristic (ROC) curve analyses were performed to assess the diagnostic performance of the prediction model and each independent predictor.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among the 111 included patients, 85 were men (76.6%). Patient age was 31\u201386\u00a0years (average age, 61.08\u2009\u00b1\u200911.50\u00a0years). After the first treatment session, 56\/111 (50.5%) patients showed an objective response (complete response\u2009+\u2009partial response), whereas the remaining showed non-response (stable disease\u2009+\u2009local progressive disease). In the univariate analysis, we identified irregular margins, number of nodules, and satellite nodules as predictors of early objective response. However, in the multivariate logistic regression analysis, irregular margins, number of nodules and pretreatment platelet were identified as the independent predictors of early objective response. A combined prediction model was then established, which factored in irregular margins, the number of nodules, and the pretreatment platelet count. This model showed good diagnostic performance (area under the ROC curve\u2009=\u20090.755), with the sensitivity, specificity, positive predictive value, and negative predictive value being 78.6%, 69.1%, 72.1%, and 76.0%, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Irregular margins, the number of nodules and the pretreatment platelet count are independent predictors of the early response of HCC to TACE. Our clinical combined model can provide a superior predictive power to a single indicator.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12880-022-00900-8","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T08:04:15Z","timestamp":1665129855000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Preoperatively predicting early response of HCC to TACE using clinical indicators and MRI features"],"prefix":"10.1186","volume":"22","author":[{"given":"Zhi-Wei","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A-Hong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da-Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Wang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen-Chang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3986-1732","authenticated-orcid":false,"given":"Zheng-Han","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,7]]},"reference":[{"issue":"2","key":"900_CR1","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatology. 2018;68(2):723\u201350.","journal-title":"Hepatology"},{"issue":"2","key":"900_CR2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s11684-014-0331-5","volume":"8","author":"R Yu","year":"2014","unstructured":"Yu R, Fan R, Hou J. Chronic hepatitis B virus infection: epidemiology, prevention, and treatment in China. Front Med. 2014;8(2):135\u201344.","journal-title":"Front Med"},{"issue":"3","key":"900_CR3","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A, Kelley RK, Galle PR, Mazzaferro V, Salem R, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681\u201393.","journal-title":"J Hepatol"},{"issue":"4","key":"900_CR4","first-page":"348","volume":"32","author":"L Bolondi","year":"2012","unstructured":"Bolondi L, Burroughs A, Dufour JF, Galle PR, Mazzaferro V, Piscaglia F, et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis. 2012;32(4):348\u201359.","journal-title":"Semin Liver Dis"},{"issue":"11","key":"900_CR5","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1111\/liv.12844","volume":"35","author":"A Sciarra","year":"2015","unstructured":"Sciarra A, Ronot M, Di Tommaso L, Raschioni C, Castera L, Belghiti J, et al. TRIP: a pathological score for transarterial chemoembolization resistance individualized prediction in hepatocellular carcinoma. Liver Int. 2015;35(11):2466\u201373.","journal-title":"Liver Int"},{"issue":"6","key":"900_CR6","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1007\/s00330-015-3982-y","volume":"26","author":"G Vesselle","year":"2016","unstructured":"Vesselle G, Quirier-Leleu C, Velasco S, Charier F, Silvain C, Boucebci S, et al. Predictive factors for complete response of chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma. Eur Radiol. 2016;26(6):1640\u20138.","journal-title":"Eur Radiol"},{"issue":"1099","key":"900_CR7","doi-asserted-by":"publisher","first-page":"20190073","DOI":"10.1259\/bjr.20190073","volume":"92","author":"H Zhang","year":"2019","unstructured":"Zhang H, He X, Yu J, Song W, Liu X, Liu Y, et al. Preoperative MRI features and clinical laboratory indicators for predicting the early therapeutic response of hepatocellular carcinoma to transcatheter arterial chemoembolization combined with High-intensity focused ultrasound treatment. Br J Radiol. 2019;92(1099):20190073.","journal-title":"Br J Radiol"},{"issue":"2","key":"900_CR8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/hepr.12912","volume":"48","author":"T Hatanaka","year":"2018","unstructured":"Hatanaka T, Arai H, Shibasaki M, Tojima H, Takizawa D, Toyoda M, et al. Factors predicting overall response and overall survival in hepatocellular carcinoma patients undergoing balloon-occluded transcatheter arterial chemoembolization: a retrospective cohort study. Hepatol Res. 2018;48(2):165\u201375.","journal-title":"Hepatol Res"},{"issue":"3","key":"900_CR9","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1148\/radiol.13130591","volume":"270","author":"V Vandecaveye","year":"2014","unstructured":"Vandecaveye V, Michielsen K, De Keyzer F, Laleman W, Komuta M, De Beeck Op K, et al. Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome. Radiology. 2014;270(3):747\u201357.","journal-title":"Radiology"},{"issue":"8","key":"900_CR10","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.7150\/jca.32491","volume":"11","author":"ZG Yuan","year":"2020","unstructured":"Yuan ZG, Wang ZY, Xia MY, Li FZ, Li Y, Shen Z, et al. Diffusion kurtosis imaging for assessing the therapeutic response of transcatheter arterial chemoembolization in hepatocellular carcinoma. J Cancer. 2020;11(8):2339\u201347.","journal-title":"J Cancer"},{"issue":"3","key":"900_CR11","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1002\/jmri.25617","volume":"46","author":"L Wu","year":"2017","unstructured":"Wu L, Xu P, Rao S, Yang L, Chen C, Liu H, et al. ADC (total) ratio and D ratio derived from intravoxel incoherent motion early after TACE are independent predictors for survival in hepatocellular carcinoma. J Magn Reson Imaging. 2017;46(3):820\u201330.","journal-title":"J Magn Reson Imaging"},{"issue":"10","key":"900_CR12","doi-asserted-by":"publisher","first-page":"5663","DOI":"10.1007\/s00330-020-06931-5","volume":"30","author":"IT Schobert","year":"2020","unstructured":"Schobert IT, Savic LJ, Chapiro J, Bousabarah K, Chen E, Laage-Gaupp F, et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE. Eur Radiol. 2020;30(10):5663\u201373.","journal-title":"Eur Radiol"},{"issue":"8","key":"900_CR13","doi-asserted-by":"publisher","first-page":"827","DOI":"10.2217\/fon-2018-0591","volume":"15","author":"B Wang","year":"2019","unstructured":"Wang B, Li F, Cheng L, et al. The pretreatment platelet count is an independent predictor of tumor progression in patients undergoing transcatheter arterial chemoembolization with hepatitis B virus-related hepatocellular carcinoma. Future Oncol. 2019;15(8):827\u201339.","journal-title":"Future Oncol"},{"key":"900_CR14","unstructured":"Bashir MR. Liver reporting & data system (LI-RADS v2018). American College of Radiology. 2018. http:\/\/www.acr.org\/Clinical-Resources\/Reporting-and-Data-Systems\/LI-RADS. Accessed 16 May 2021."},{"issue":"1","key":"900_CR15","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52\u201360.","journal-title":"Semin Liver Dis"},{"issue":"3","key":"900_CR16","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1148\/radiol.2017170731","volume":"286","author":"TA Sandow","year":"2018","unstructured":"Sandow TA, Arndt SE, Albar AA, DeVun DA, Kirsch DS, Gimenez JM, et al. Assessment of response to transcatheter arterial chemoembolization with doxorubicin-eluting microspheres: tumor biology and hepatocellular carcinoma recurrence in a 5-year transplant cohort. Radiology. 2018;286(3):1072\u201383.","journal-title":"Radiology"},{"issue":"1","key":"900_CR17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/SLA.0b013e3181a77e59","volume":"250","author":"KJ Halazun","year":"2009","unstructured":"Halazun KJ, Hardy MA, Rana AA, Woodland DCT, Luyten EJ, Mahadev S, et al. Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg. 2009;250(1):141\u201351.","journal-title":"Ann Surg"},{"issue":"4","key":"900_CR18","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2214\/AJR.19.21168","volume":"213","author":"J Chen","year":"2019","unstructured":"Chen J, Zhou J, Kuang S, Zhang Y, Xie S, He B, et al. Liver imaging reporting and data system category 5: MRI predictors of microvascular invasion and recurrence after hepatectomy for hepatocellular carcinoma. AJR Am J Roentgenol. 2019;213(4):821\u201330.","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"900_CR19","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1148\/radiol.2015150998","volume":"279","author":"M Renzulli","year":"2016","unstructured":"Renzulli M, Brocchi S, Cucchetti A, Mazzotti F, Mosconi C, Sportoletti C, et al. Can current preoperative imaging be used to detect microvascular invasion of hepatocellular carcinoma? Radiology. 2016;279(2):432\u201342.","journal-title":"Radiology"},{"issue":"7","key":"900_CR20","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s11604-019-00840-4","volume":"37","author":"MM Nakano","year":"2019","unstructured":"Nakano MM, Yamamoto A, Nishida N, Hamuro M, Hamamoto S, Jogo A, et al. Risk factors for local recurrence of hepatocellular carcinoma after transcatheter arterial chemoembolization with drug-eluting beads (DEB-TACE). Jpn J Radiol. 2019;37(7):543\u20138.","journal-title":"Jpn J Radiol"},{"issue":"4","key":"900_CR21","doi-asserted-by":"publisher","first-page":"w211","DOI":"10.2214\/AJR.16.17398","volume":"209","author":"HJ Park","year":"2017","unstructured":"Park HJ, Kim JH, Choi SY, Lee ES, Park SJ, Byun JY, et al. Prediction of therapeutic response of hepatocellular carcinoma to transcatheter arterial chemoembolization based on pretherapeutic dynamic CT and textural findings. AJR Am J Roentgenol. 2017;209(4):w211\u201320.","journal-title":"AJR Am J Roentgenol"},{"issue":"10","key":"900_CR22","doi-asserted-by":"publisher","first-page":"765","DOI":"10.14740\/jocmr3559w","volume":"10","author":"K Katayama","year":"2018","unstructured":"Katayama K, Imai T, Abe Y, Nawa T, Maeda N, Nakanishi K, et al. Number of nodules but not size of hepatocellular carcinoma can predict refractoriness to transarterial chemoembolization and poor prognosis. J Clin Med Res. 2018;10(10):765\u201371.","journal-title":"J Clin Med Res"},{"key":"900_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.657039","volume":"11","author":"L Wen","year":"2021","unstructured":"Wen L, Weng S, Yan C, Ye R, Zhu Y, Zhou L, Gao L, Li Y. A radiomics nomogram for preoperative prediction of early recurrence of small hepatocellular carcinoma after surgical resection or radiofrequency ablation. Front Oncol. 2021;11: 657039.","journal-title":"Front Oncol"},{"issue":"10","key":"900_CR24","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1111\/liv.14560","volume":"40","author":"PH Liu","year":"2020","unstructured":"Liu PH, Hsu CY, Su CW, Huang YH, Hou MC, Rich NE, Fujiwara N, Hoshida Y, Singal AG, Huo TI. Thrombocytosis is associated with worse survival in patients with hepatocellular carcinoma. Liver Int. 2020;40(10):2522\u201334.","journal-title":"Liver Int"},{"issue":"3","key":"900_CR25","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1440-1746.2007.05120.x","volume":"23","author":"K Nouso","year":"2008","unstructured":"Nouso K, Matsumoto E, Kobayashi Y, Nakamura S, Tanaka H, Osawa T, Ikeda H, Araki Y, Sakaguchi K, Shiratori Y. Risk factors for local and distant recurrence of hepatocellular carcinomas after local ablation therapies. J Gastroenterol Hepatol. 2008;23(3):453\u20138.","journal-title":"J Gastroenterol Hepatol"},{"key":"900_CR26","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jss.2016.11.002","volume":"210","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, Zhang Y, Wang W, Hua Y, Liu L, Shen S, Peng B. Thrombocytopenia and the outcomes of hepatectomy for hepatocellular carcinoma: a meta-analysis. J Surg Res. 2017;210:99\u2013107.","journal-title":"J Surg Res"},{"issue":"8","key":"900_CR27","first-page":"2891","volume":"26","author":"R Iezzi","year":"2022","unstructured":"Iezzi R, Cas\u00e0 C, Posa A, Cornacchione P, Carchesio F, Boldrini L, Tanzilli A, Cerrito L, Fionda B, Longo V, et al. Project for interventional oncology large-database in liver hepatocellular carcinoma - preliminary CT-based radiomic analysis (POLAR Liver 1.1). Eur Rev Med Pharmacol Sci. 2022;26(8):2891\u20139.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"6","key":"900_CR28","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1159\/000448999","volume":"91","author":"T Ichikawa","year":"2016","unstructured":"Ichikawa T, Machida N, Sasaki H, Tenmoku A, Kaneko H, Negishi R, Oi I, Fujino MA. Early prediction of the outcome using tumor markers and mRECIST in unresectable hepatocellular carcinoma patients who underwent transarterial chemoembolization. Oncology. 2016;91(6):317\u201330.","journal-title":"Oncology"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-022-00900-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-022-00900-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-022-00900-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T08:06:44Z","timestamp":1665130004000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedimaging.biomedcentral.com\/articles\/10.1186\/s12880-022-00900-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,7]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["900"],"URL":"https:\/\/doi.org\/10.1186\/s12880-022-00900-8","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,7]]},"assertion":[{"value":"23 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Review Committee of Beijing Friendship Hospital, Capital Medical University. All methods were carried out in accordance with relevant guidelines and regulations, and written informed consent was waived due to its retrospective nature.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"176"}}